IMBdx

IMBdx is a Korean startup founded in July 2018 that listed on KOSDAQ on April 3, 2024 through the technology special listing track, receiving the highest A-grade ratings from both Korea Rating Data and SCI Pyeongga Jeongbo during the process.

Its product lineup consists of the profiling product 'AlphaLiquid' used for precision diagnosis and treatment of advanced cancer, the recurrence-monitoring product 'CancerDetect' that detects minimal residual disease after surgery, and the screening product 'CancerFind' for multi-cancer early detection, covering the full cancer care continuum.

In Korea, on-site prescriptions are available at more than 30 major hospitals including Seoul National University Hospital and Samsung Medical Center, while overseas the company has expanded into 23 countries including Europe, Japan and India since entering Taiwan in 2021.

Its flagship product AlphaLiquid100 holds the No.1 domestic market share, and as of a 2024 assessment it had captured close to 90 percent of all reimbursed NGS liquid biopsy prescriptions.

As of the first quarter of 2024, product mix was led by AlphaLiquid100 at 71 percent, followed by AlphaLiquid HRR at 6 percent, CancerDetect at 13 percent and CancerFind at 8 percent, with the profiling segment (AlphaLiquid100 and HRR) accounting for 77 percent of total revenue as the company's cash cow.

More recently the company launched AlphaLiquid Breast, a blood-based molecular diagnostic that analyzes key breast cancer treatment genes in a single test, and expanded its HRR gene panel from 15 to 19 genes, and is running a platform strategy spanning the patient lifecycle through AlphaLiquid1000, which expands gene coverage tenfold, and AlphaLiquid Breast, adopted for an AstraZeneca breast cancer research project.

On the global partnership front, its diagnostic services are supplied to roughly 30 countries across the Middle East, Europe and the Americas through AstraZeneca's PROSPER 2.0 project, and in the United States it entered the market by signing a supply agreement with Inocras.

Competitively, it faces Cytogen, a leading domestic liquid biopsy player, with differing analytical targets—circulating tumor DNA fragments versus circulating tumor cells (CTC), while globally Guardant Health, which launched a product analyzing about 700 genes, is cited as a key competitor.

IMBdx's 2025 consolidated revenue came to KRW 5.329 billion, up 56.4 percent from KRW 3.407 billion in 2024, surpassing the 2023 level (KRW 4.027 billion) and putting revenue back on a growth track.

However, actual results fell short of a market estimate at the time that revenue through the third quarter of the prior year was KRW 3.6 billion, with full-year revenue expected to come in around KRW 6.5 billion.

Operating loss narrowed 18.4 percent to KRW 8.664 billion in 2025 from KRW 10.612 billion in 2024, though it remained wider than the 2023 figure of KRW 7.769 billion. Operating margin improved from -311.5 percent in 2024 to -162.6 percent in 2025, but did not recover to the 2023 level of -192.9 percent.

Net loss attributable to owners narrowed for three straight years, from KRW 10.416 billion in 2023 to KRW 9.577 billion in 2024 and KRW 7.934 billion in 2025.

On a quarterly basis, revenue fell to KRW 1.115 billion in the third quarter of 2025, recovered to KRW 1.701 billion in the fourth quarter, dipped again to KRW 1.274 billion in the first quarter of 2026, and rose to KRW 1.509 billion in the second quarter, showing fluctuation rather than a steady upward trajectory.

Operating loss widened to KRW 2.568 billion in the third quarter of 2025 before narrowing to KRW 1.407 billion in the second quarter of 2026, the smallest loss in the recent four-quarter window, while net loss attributable to owners also narrowed to KRW 1.062 billion in the same period, signaling some improvement.

Operating cash flow was negative by a similar magnitude each year—KRW -6.231 billion in 2023, KRW -6.647 billion in 2024, and KRW -6.202 billion in 2025—and equity declined from KRW 32.454 billion in 2024 to KRW 25.165 billion in 2025 as a result. The debt ratio stood at a low 7.8 percent in 2025, indicating limited balance-sheet risk itself.

Liquid biopsy is a fast-growing field owing to its convenience and sensitivity advantages over tissue biopsy, though estimates vary by market research firm.

The global liquid biopsy market was projected to grow from KRW 17 trillion in 2024 to KRW 33 trillion by 2030, a compound annual growth rate of 11.5 percent, while another estimate put growth at from KRW 10.4 trillion in 2023 to KRW 76.2 trillion by 2032, a CAGR of 25.3 percent.

The broader cancer diagnostics market that liquid biopsy belongs to is expected to grow from KRW 158 trillion in 2024 to KRW 224 trillion by 2030, a CAGR of 6.14 percent, meaning liquid biopsy is growing faster than the overall market.

In Korea, the substitution rate of liquid biopsy for tissue biopsy is still around 7 percent, an early stage, and the company itself has cited crossing a 10 percent substitution rate as a key condition for reaching quarterly breakeven.

The reimbursed NGS market has grown at roughly 20 percent annually since 2019, though an adjustment to selective coverage criteria that slightly raised patient co-payments could slow the growth rate of prescriptions.

Competitively, IMBdx maintains the No.1 domestic market share for AlphaLiquid100, facing Cytogen's CTC-based technology domestically and Guardant Health as a major global rival.

Overseas, following its Taiwan entry the company secured the No.2 market share position in Taiwan and continues to expand its partnership network into Japan and Thailand.

The company has set a 2026 revenue target of KRW 10 billion and expects a quarterly operating profit turnaround to be achievable, a target roughly 88 percent above 2025's confirmed revenue of KRW 5.3 billion that would require an acceleration in revenue growth from the second half onward.

In a January 2026 report, the Korea IR Association forecast that IMBdx could break even in the second half of 2026, citing expanding test volumes through health checkup centers and the acceleration of overseas market entry.

On the product roadmap, AlphaLiquid1000, which analyzes 1,000 genes, was commercialized in the first half of 2026 with tenfold expanded gene coverage, and the number of cancer types detectable by CancerFind has been expanded to 12.

Through a government-linked project, the company was selected as the lead firm for a Korea-type ARPA-H program to expand CancerFind's detectable cancer types to 30.

Overseas, its diagnostic services are being supplied to roughly 30 countries through AstraZeneca's PROSPER 2.0 project, and new regional partnerships continue, including a clinical research collaboration with Chulabhorn Hospital in Thailand.

These targets and projects, however, remain subject to change based on company planning and government program progress, and the actual timing of revenue and earnings impact will need to be confirmed through future quarterly disclosures.